Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received ...
Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT®, its validated genomic test that provides individualized ...
Risk of recurrence and progression of ductal carcinoma in situ (DCIS) to invasive cancer remains uncertain, emphasizing the need for developing predictive biomarkers of aggressive DCIS. 194 primary ...
Add Yahoo as a preferred source to see more of our stories on Google. After a breast biopsy at age 40, Rawan Kajo was given two options: Surgeons could remove one breast, or both. Kajo, a pharmacist ...
Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment ...
Many women diagnosed with ductal carcinoma in situ (DCIS) have inaccurate perceptions of their breast cancer risks, according to a study published online February 12 in the Journal of the National ...
Predicting nipple-areolar involvement using preoperative breast MRI and primary tumor characteristics. Background: Ductal carcinoma in situ (DCIS) is a heterogeneous and potentially curable disease ...
Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received ...
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is ...
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet ...
Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ...
DCIS, often called Stage Zero breast cancer, is the earliest stage and often diagnosed via mammogram, with no symptoms. In most cases, DCIS will not turn into a life-threatening tumor, but doctors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results